Patents by Inventor Queenie VONG
Queenie VONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952408Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: GrantFiled: September 28, 2018Date of Patent: April 9, 2024Assignees: Juno Therapeutics, Inc., Editas Medicine, Inc.Inventors: Cameron Brandt, Brian Belmont, Christopher Borges, Stephen Michael Burleigh, Alexandra Croft, Stephen Jacob Goldfless, David Jeffrey Huss, Yue Jiang, Timothy G. Johnstone, David Koppstein, Hieu Nguyen, Christopher Heath Nye, Haley Peper, Blythe D. Sather, Sonia Timberlake, Dean Y. Toy, Queenie Vong, Gordon Grant Welstead, James Sissons
-
Publication number: 20230310605Abstract: Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to express a ROR1-binding protein and have increased level of c-Jun protein. In some aspects, the immune cells are administered to a subject in need thereof.Type: ApplicationFiled: October 27, 2022Publication date: October 5, 2023Applicant: Lyell Immunopharma, Inc.Inventors: Suman Kumar VODNALA, Veena KRISHNAMOORTHY, Spencer PARK, Queenie VONG, Blythe SATHER
-
Publication number: 20230313138Abstract: Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to overexpress c-Jun and/or comprise one or more exogenous nucleotide sequences encoding a ligand binding protein. In some aspects, the immune cells are administered to a subject in need thereof.Type: ApplicationFiled: October 27, 2022Publication date: October 5, 2023Applicant: Lyell Immunopharma, Inc.Inventors: Suman Kumar VODNALA, Veena KRISHNAMOORTHY, Spencer PARK, Queenie VONG, Blythe SATHER
-
Publication number: 20230061455Abstract: CRISPR/CAS-related genome editing systems, compositions and methods for targeting the TGFBR2 locus, as well as cells edited using these systems, compositions and methods are provided.Type: ApplicationFiled: November 1, 2018Publication date: March 2, 2023Inventors: Stephen Michael BURLEIGH, Melissa CHIN, Fred HARBINSKI, Christopher Heath NYE, Blythe D. SATHER, Queenie VONG, Gordon Grant WELSTEAD, Chris WILSON
-
Publication number: 20230022654Abstract: The present disclosure relates to polynucleotides encoding a chimeric polypeptide comprising a c-Jun polypeptide, a ROR1-binding protein, and a truncated EGF receptor. Also provided are cells (e.g., T cells) expressing CARs comprising a ROR1-binding protein and overexpressing a c-Jun polypeptide. Overexpression of c-Jun in CAR T cells confers improved properties, e.g., reducing or preventing exhaustion.Type: ApplicationFiled: February 24, 2022Publication date: January 26, 2023Applicant: Lyell Immunopharma, Inc.Inventors: Spencer PARK, Queenie VONG, Blythe SATHER, Byoung RYU, Marc LAJOIE, Howell MOFFETT, Brian WEITZNER, Yun SONG, Scott BOYKEN, Neeraj SHARMA, Shobha POTLURI, Bijan BOLDAJIPOUR
-
Publication number: 20220307039Abstract: Disclosed herein are polynucleotides comprising a nucleotide sequence encoding an AP-1 transcription factor (i.e., c-Jun). In some aspects, the nucleotide sequence is codon-optimized. In some aspects, the polynucleotides comprise one or more additional nucleotide sequences encoding a linker, signal peptide, antigen-binding domain, spacer, transmembrane domain, costimulatory domain, intracellular signaling domain, truncated EGFR, and combinations thereof. Also disclosed herein are cells, vectors, and pharmaceutical compositions comprising such polynucleotides. The use of such polynucleotides, cells, vectors, and pharmaceutical compositions to treat a disease or disorder (e.g., cancer) is also provided.Type: ApplicationFiled: February 24, 2022Publication date: September 29, 2022Applicant: Lyell Immunopharma, Inc.Inventors: Spencer PARK, Queenie VONG, Blythe SATHER, Byoung RYU, Marc LAJOIE
-
Publication number: 20220184131Abstract: Provided herein are engineered immune cells, e.g. T cells, expressing a recombinant receptor, that contain a modified transforming growth factor-beta receptor type-2 (TGFBR2) locus encoding the recombinant receptor or a portion thereof. In some aspects, the cells are engineered by targeted integration of a transgene sequence encoding the recombinant receptor or a portion thereof, at a TGFBR2 genomic locus. Also provided are cell compositions containing the engineered immune cells, nucleic acids for engineering cells, and methods, kits and articles of manufacture for producing the engineered cells, such as by targeting a transgene sequence encoding a recombinant receptor or a portion thereof for integration into a region of a TGFBR2 genomic locus. In some embodiments, the engineered cells, e.g. T cells, can be used in connection with cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered cells.Type: ApplicationFiled: April 30, 2020Publication date: June 16, 2022Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.Inventors: Stephen Michael Burleigh, Cedric CLEYRAT, Melissa CHIN, Fred HARBINSKI, Christopher Heath NYE, Blythe D. SATHER, Queenie VONG, G. GRANT WELSTEAD, Christopher WILSON
-
Publication number: 20210284709Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: ApplicationFiled: September 28, 2018Publication date: September 16, 2021Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.Inventors: Cameron BRANDT, Brian BELMONT, Christopher BORGES, Stephen Michael BURLEIGH, Alexandra CROFT, Stephen Jacob GOLDFLESS, David Jeffrey HUSS, Yue JIANG, Timothy G. JOHNSTONE, David KOPPSTEIN, Hieu NGUYEN, Christopher Heath NYE, Haley PEPER, Blythe D. SATHER, Sonia TIMBERLAKE, Dean Y. TOY, Queenie VONG, Gordon Grant WELSTEAD, James SISSONS
-
Publication number: 20210017249Abstract: Provided are methods for engineering immune cells, cell compositions containing engineered immune cells, kits and articles of manufacture for targeting nucleic acid sequence encoding a recombinant receptor to a particular genomic locus and/or for modulating expression of the gene at the genomic locus, and applications thereof in connection with cancer immunotherapy comprising adoptive transfer of engineered T cells. These may involve genetic disruption of at least one site within a TRAC gene and/or a TRBC gene and integration of the transgene encoding for the recombinant receptor at or near one of the at least one target site.Type: ApplicationFiled: April 3, 2019Publication date: January 21, 2021Applicants: Juno Therapeutics, Inc., Editas Medicine, lnc.Inventors: Blythe D. SATHER, Christopher BORGES, Stephen Michael BURLEIGH, Christopher Heath NYE, Queenie VONG, Gordon Grant WELSTEAD
-
Publication number: 20210015869Abstract: Provided herein are methods for engineering immune cells, cell compositions containing engineered immune cells, kits and articles of manufacture for targeting nucleic acid sequence encoding a portion of a recombinant receptor, e.g., a recombinant T cell receptor (TCR), to a particular genomic locus and/or for modulating expression of the gene at the genomic locus, and applications thereof in connection with cancer immunotherapy, such as adoptive transfer of engineered T cells. In some aspects, the nucleic acid sequence integrates in-frame into the locus of a receptor encoding gene, and in some aspects, results in expression of the whole recombinant receptor.Type: ApplicationFiled: April 3, 2019Publication date: January 21, 2021Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.Inventors: Stephen Michael BURLEIGH, Christopher BORGES, Christopher Heath NYE, Blythe D. SATHER, Queenie VONG, Gordon Grant WELSTEAD